We are writing an article for a physician readership on the potential of brain chips in the treatment of paralysis. We are looking for concise, quick, and clinically grounded quotes from physicians, neurologists, neurosurgeons, and rehabilitation specialists to address the following: What are the main surgical and neurological risks of implanting ultra-thin electrode arrays in the motor cortex? How clinically significant is electrode retraction, as seen in early Neuralink patients, and what strategies exist to mitigate it? What long-term safety concerns (gliosis, infection, device failure) are most relevant to implanted BCI devices? What clinical endpoints should be prioritized in evaluating the bran-computer interface (BCI) success for patients with quadriplegia?

I've spent 17 years managing complex neuromodulation devices and have implanted hundreds of spinal cord stimulators and peripheral nerve stimulators, so I understand the surgical and long-term risks of neural interface devices. The motor cortex presents unique challenges--electrode migration is far more problematic there than in spinal applications due to brain movement and cerebrospinal fluid dynamics. The main surgical risks include hemorrhage during implantation (similar to what we see with deep brain stimulation) and immediate post-operative swelling that can affect motor function. Neurologically, the motor cortex is unforgiving--even minimal tissue disruption can cause weakness or seizures. I've seen electrode migration in spinal cord stimulators require repositioning in about 8-12% of cases, but brain tissue is far less stable. Electrode retraction is clinically significant because signal quality degrades rapidly with distance from target neurons. In my spinal stimulator experience, even 1-2mm of lead migration can eliminate therapeutic benefit entirely. For brain chips, this likely means complete loss of motor signal capture. Better anchoring systems and more flexible electrode designs are essential--we've learned this from decades of cardiac pacemaker evolution. Long-term, gliosis is my biggest concern--I've seen scar tissue formation around spinal implants reduce efficacy over 2-3 years. In brain tissue, this inflammatory response could be more severe. For quadriplegic patients, I'd prioritize functional endpoints: ability to control a computer cursor, type speed, and activities of daily living scores. These matter more than raw signal strength because they directly impact independence and quality of life.